Josh Hardman, founder of Psychedelic Alpha, delves into the evolving psychedelic industry landscape, job opportunities, challenges in fundraising, therapy protocols, investor sentiment, and the significance of reciprocity and collaboration in the industry.

In this engaging discussion, Josh Hardman, founder and editor of Psychedelic Alpha, tackles the FDA's recent rejection of MDMA for PTSD therapy. He explores the complexities of the FDA advisory process and highlights the challenges in data gaps and potential biases in clinical trials. Hardman delves into the future of psychedelic treatments and the rising importance of non-hallucinogenic therapies. The conversation also touches on the implications for insurance coverage and regulatory pathways, painting a vivid picture of the evolving landscape in mental health treatment.

Josh Hardman, founder of Psychedelic Alpha, discusses the challenges faced by the psychedelic industry including progress of decriminalisation, clinical trial milestones, and the potential evolution of the industry. They also touch on the current state of decriminalization in Oregon and Colorado, challenges in accessing regulated psilocybin, real-world evidence collection, drug development models, and the importance of in-person events in the psychedelic industry.